Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study

Area of Science:

• Oncology
• Genomics
• Precision Medicine

Background:

• Refractory cancers pose challenges for early-phase clinical trials.
• Molecular diagnostics can stratify patients for targeted therapies.
• Identifying patients likely to respond to novel treatments is crucial.

Purpose of the Study:

• To evaluate the utility of comprehensive genomic profiling (CGP) in patients with diverse refractory cancers.
• To assess the association between genomic alterations and treatment response.
• To determine if CGP can guide therapy selection for improved clinical outcomes.

Main Methods:

• Prospective, single-center study of 500 patients with refractory cancers.
• Comprehensive genomic profiling (CGP) using next-generation sequencing (236 genes).
• Analysis of molecular alterations, matching scores, and clinical outcomes (stable disease, treatment failure, survival).

Main Results:

• 93.5% of successfully profiled patients (339/500) had at least one actionable alteration.
• 188 patients received matched or unmatched therapy.
• High matching scores were independently associated with higher rates of stable disease/remission (P=0.024), longer time-to-treatment failure (HR=0.52, P=0.0003), and improved survival (HR=0.65, P=0.05).

Conclusions:

• CGP is a valuable tool for assigning therapy to patients with refractory malignancies.
• The study provides a clinical proof of concept for CGP in guiding treatment decisions.
• CGP is particularly useful for patients with multiple genomic aberrations, potentially enabling combination therapies.